To include your compound in the COVID-19 Resource Center, submit it here.
SRGN published data from separate Phase I trials of DAB486IL-2 in chemotherapy-resistant cancer patients. Data from
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury